Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin

Review

(4111) Total Article Views

Authors: Ravi K Ramana, Bruce E Lewis

Published Date June 2008 Volume 2008:4(3) Pages 493 - 505

DOI: http://dx.doi.org/10.2147/VHRM.S2455

Ravi K Ramana, Bruce E Lewis

Division of Cardiology, Loyola University Medical Center, Maywood, Illinois, USA

Abstract: Previously, indirect thrombin inhibitors such as unfractionated heparin or low-molecular-weight heparin were used as a standard anticoagulation during percutaneous coronary intervention to prevent procedural thrombotic complications but at a risk of hemorrhagic complications. More recently, bivalirudin, a member of the direct thrombin inhibitor class, has been shown to have 1) predictable pharmacokinetics, 2) ability to inhibit free- and clot-bound thrombin, 3) no properties of platelet activation, 4) avoidance of heparin-induced thrombocytopenia, and 5) a significant reduction of bleeding without a reduction in thrombotic or ischemic endpoints compared to heparin and glycoprotein IIbIIIa inhibitors when used in patients presenting with acute coronary syndrome who are planned for an invasive treatment strategy.

Keywords: bivalirudin, coronary intervention, direct thrombin inhibitor, acute coronary syndrome

Readers of this article also read: